פרוגרף 1 מג ישראל - עברית - Ministry of Health

פרוגרף 1 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 5 מג ישראל - עברית - Ministry of Health

פרוגרף 5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 5 מג ישראל - עברית - Ministry of Health

פרוגרף 5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 0.5 מג ישראל - עברית - Ministry of Health

פרוגרף 0.5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 0.5 מג ישראל - עברית - Ministry of Health

פרוגרף 0.5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

גילניה 0.5 מג ישראל - עברית - Ministry of Health

גילניה 0.5 מג

novartis israel ltd - fingolimod as hydrochloride - קפסולה קשיחה - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disabiliry.

רבלימיד 5 מג ישראל - עברית - Ministry of Health

רבלימיד 5 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 5 מג ישראל - עברית - Ministry of Health

רבלימיד 5 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 10 מג ישראל - עברית - Ministry of Health

רבלימיד 10 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 10 מג ישראל - עברית - Ministry of Health

רבלימיד 10 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.